American Society of Hematology

Figure 2.

$Mixed model with repeated measures for change from baseline for exploratory EORTC QLQ-C30 functional scales (QoL analysis set). Results populated only through month 15 due to lack of model convergence when using time points. For EORTC QLQ-C30 domains, figures are based on model 1. Horizontal lines represent the minimally important difference thresholds for clinically meaningful change and are provided for clarity of interpretation. This model included variables for treatment, time, and treatment by time interaction (primary analysis) and controlled for response to first-line therapy (primary refractory, relapse = 6 months of first-line therapy vs relapse > 6 and = 12 months of first-line therapy) and age-adjusted IPI (0-1 vs 2-3) at time of screening. Patients who had PRO assessments after an EFS event (supplemental Results) were not censored to avoid biasing results by excluding patients with worse outcomes. ∗P < .05.$

Mixed model with repeated measures for change from baseline for exploratory EORTC QLQ-C30 functional scales (QoL analysis set). Results populated only through month 15 due to lack of model convergence when using time points. For EORTC QLQ-C30 domains, figures are based on model 1. Horizontal lines represent the minimally important difference thresholds for clinically meaningful change and are provided for clarity of interpretation. This model included variables for treatment, time, and treatment by time interaction (primary analysis) and controlled for response to first-line therapy (primary refractory, relapse = 6 months of first-line therapy vs relapse > 6 and = 12 months of first-line therapy) and age-adjusted IPI (0-1 vs 2-3) at time of screening. Patients who had PRO assessments after an EFS event (supplemental Results) were not censored to avoid biasing results by excluding patients with worse outcomes. ∗P < .05.

This Feature Is Available To Subscribers Only